Analysts Issue Forecasts for WVE Q1 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) – Stock analysts at B. Riley issued their Q1 2025 earnings per share estimates for shares of Wave Life Sciences in a report issued on Wednesday, November 13th. B. Riley analyst M. El-Saadi anticipates that the company will post earnings of ($0.25) per share for the quarter. B. Riley currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.06) per share. B. Riley also issued estimates for Wave Life Sciences’ Q2 2025 earnings at ($0.24) EPS.

Several other equities research analysts have also commented on the company. Raymond James raised Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and boosted their price target for the stock from $13.00 to $22.00 in a research note on Wednesday, October 16th. Leerink Partners upped their target price on Wave Life Sciences from $20.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. StockNews.com cut Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday. Truist Financial increased their price objective on shares of Wave Life Sciences from $17.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a research report on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Wave Life Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $21.89.

Wave Life Sciences Trading Down 8.9 %

Shares of WVE opened at $13.67 on Friday. The firm has a market capitalization of $1.71 billion, a PE ratio of -12.32 and a beta of -1.20. The stock’s 50 day moving average is $10.76 and its two-hundred day moving average is $7.52. Wave Life Sciences has a twelve month low of $3.50 and a twelve month high of $16.74.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.19). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The company had revenue of ($7.68) million during the quarter, compared to analyst estimates of $15.45 million.

Insider Buying and Selling

In other news, insider Chris Francis sold 36,000 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $576,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paul Bolno sold 51,234 shares of the stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $14.32, for a total transaction of $733,670.88. Following the completion of the sale, the chief executive officer now owns 217,351 shares of the company’s stock, valued at approximately $3,112,466.32. The trade was a 19.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 452,056 shares of company stock worth $5,955,438 in the last ninety days. 29.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Wave Life Sciences

Large investors have recently bought and sold shares of the business. Privium Fund Management B.V. acquired a new position in Wave Life Sciences during the 3rd quarter valued at $400,000. Moody Aldrich Partners LLC lifted its stake in shares of Wave Life Sciences by 69.0% in the third quarter. Moody Aldrich Partners LLC now owns 303,062 shares of the company’s stock valued at $2,485,000 after buying an additional 123,703 shares during the period. SG Americas Securities LLC acquired a new stake in Wave Life Sciences during the second quarter worth about $668,000. Vanguard Group Inc. increased its stake in Wave Life Sciences by 39.7% during the first quarter. Vanguard Group Inc. now owns 1,834,090 shares of the company’s stock valued at $11,316,000 after acquiring an additional 521,665 shares during the period. Finally, Driehaus Capital Management LLC raised its holdings in Wave Life Sciences by 62.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 908,096 shares of the company’s stock valued at $4,531,000 after acquiring an additional 348,300 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.